Pharmacotherapy for post-traumatic stress disorder : a systematic review and meta-analysis by Ipser, Jonathan et al.
October 2006, Vol. 96, No. 10  SAMJ
ORIGINAL ARTICLES
1088
Although the phenomenon of post-traumatic stress disorder 
(PTSD) has long been recognised (for example as ‘shell shock’ 
or ‘combat neurosis’), it is only relatively recently that this 
disorder has been officially recognised in the psychiatric 
nomenclature.1 The personal, social and economic burden 
of PTSD has become increasingly apparent owing to the 
prevalence (estimated at lifetime rates of between 5% and 10% 
of the adult population2) and chronicity of the condition, and 
because of the high psychiatric and medical co-morbidity and 
impaired quality of life associated with it. 
   PTSD is defined in the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV)3 as the psychological sequela of 
exposure to ‘actual or threatened death or serious injury, or 
threat to the physical integrity of self or others’, and in which  
‘the person’s response involved intense fear, helplessness or 
horror’. PTSD symptoms can be grouped into the following 
symptom clusters: intrusive/re-experiencing (e.g. flashbacks, 
nightmares), avoidant/numbing (e.g. loss of interest, 
detachment), and hyperarousal (e.g. irritability and difficulty 
concentrating and sleeping). 
   Psychotherapy has traditionally been the treatment of choice 
for PTSD. Nevertheless, a rationale for the use of medication 
treatments can be found in the increasing recognition that 
this disorder is characterised by specific psychobiological 
dysfunctions and the lack of evidence for the effectiveness of 
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Background. Post-traumatic stress disorder (PTSD) is a prevalent 
and disabling condition.  Evidence that PTSD is characterised 
by specific psychobiological dysfunctions has contributed to a 
growing interest in use of medication in its treatment.
Objectives. To assess the effects of medication in the treatment of 
PTSD.
Design. Systematic review of randomised controlled trials 
(RCTs) following the Cochrane Collaboration guidelines. 
A more detailed version of the review is published in the 
Cochrane Database of Systematic Reviews.
Methods. We searched the Cochrane Depression, Anxiety and 
Neurosis Group specialised register, the Cochrane Central 
Register of Controlled Trials (Cochrane Library issue 4, 2004), 
MEDLINE (January 1966 - December 2004), PsycINFO (1966 - 
2004), the National PTSD Center Pilots database, and the meta 
register module of the Controlled Trials database. Reference lists 
of retrieved articles were searched for additional studies. 
Two raters independently assessed RCTs for inclusion in 
the review, collated trial data, and assessed trial quality. 
Investigators were contacted to obtain missing data. Summary 
statistics were stratified by medication class, and by medication 
agent for the selective serotonin re-uptake inhibitors (SSRIs). 
Dichotomous and continuous measures were calculated using 
a random effects model, heterogeneity was assessed, and 
subgroup/sensitivity analyses were done. 
Main results. Thirty-five short-term (14 weeks or less) RCTs 
were included in the analysis (4 597 participants). Symptom 
severity for 17 trials was significantly reduced in the medication 
groups, relative to placebo (weighted mean difference (WMD) 
= −5.76, 95% confidence interval (CI):  −8.16 - −3.36, N = 2 507). 
Similarly, summary statistics for responder status from 13 trials 
demonstrated overall superiority of a variety of medication 
agents compared with placebo (relative risk (RR) = 1.49, 95% 
CI: 1.28, 1.73, number needed to treat (NNT) = 4.85, N = 1 272). 
Medication and placebo response occurred in 59.1% (N = 644) 
and 38.5% (N = 628) of patients, respectively. Of the medication 
classes, evidence of treatment efficacy was most convincing for 
the SSRIs.
Medication was also effective in reducing the severity of the 
PTSD re-experiencing/intrusion, avoidance/numbing, and 
hyperarousal symptom clusters in 9 trials (N = 1 304). In 
addition, medication was superior to placebo in reducing co-
morbid depression and disability. Medication was also less well 
tolerated than placebo. A narrative review of the 3 maintenance 
trials suggested that long-term medication may be required in 
treating PTSD.  
Conclusion. Medication treatments can be effective in treating 
PTSD, acting to reduce its core symptoms, as well as associated 
depression and disability, and should be considered as 
part of the treatment of this disorder.  The findings of this 
review support the status of SSRIs as first-line agents in the 
pharmacotherapy of PTSD, as well as their value in long-
term treatment. However, there remain important gaps in the 
evidence base, and there is a continued need for more effective 
agents in the management of PTSD.
S Afr Med J 2006; 96: 1088-1096.
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certain commonly employed psychotherapeutic interventions 
(such as psychological debriefing4). In addition, several 
psychiatric disorders are often found co-morbid with PTSD 
disorders,2 and certain of these are known to respond to 
medication.
   Systematic review of the pharmacotherapy studies may be 
useful in tackling several questions. First, is pharmacotherapy 
in fact an effective form of treatment in PTSD? Given the 
preponderance of psychological models and evidence for the 
efficacy of certain forms of psychotherapy in treating PTSD,5,6 
the role of pharmacotherapy remains debatable for many.  
   Second, are particular medication classes more effective in 
the treatment of symptoms and/or more acceptable to the 
patient in terms of adverse events than others?  Some sources7 
have suggested that the serotonin re-uptake inhibitors (SSRIs) 
nefazodone and venlafaxine are first-line medications for 
the treatment of PTSD, with benzodiazepines and mood-
stabilisers having a role to play in treating patients with certain 
kinds of symptoms. Others have highlighted paroxetine and 
mirtazapine.6  
   Third, can a systematic review of randomised controlled 
trials (RCTs) provide information on the most important factors 
affecting pharmacotherapy response?  Treatment response 
may be affected by clinical factors (e.g. duration of symptoms, 
the kind of pre-existing trauma (e.g. combat-related), and the 
presence of co-morbid depression), as well as methodological 
factors (e.g. medication dosage and trial duration).  
   This review represents a systematic attempt to answer these 
questions through adhering to the guidelines prescribed by the 
Cochrane Collaboration. A more detailed version of this review 
is published in the Cochrane Database of Systematic Reviews.8
Methods
Identification of clinical trials
We considered for inclusion all RCTs on the pharmacotherapy 
of PTSD in which patients diagnosed with this condition were 
randomised to either a medication or a comparison group 
(placebo or other medication). Candidate trials were identified 
through searching MEDLINE (January 1966 - December 2004), 
the Cochrane Central Register of Controlled Trials (issue 4, 
2004), the Cochrane Collaboration Depression, Anxiety and 
Neurosis Controlled Trials Register, PsycINFO (1966 - 2004), 
the National PTSD Center Pilots database and the metaRegister 
module (mRCT) of the Controlled Trials database (please refer 
to the Cochrane Review8 for the queries used). Reference lists of 
retrieved articles were searched for additional studies. 
   RCTs identified from the search were independently assessed 
for inclusion by two raters, based on information included in 
the trial report. Any disagreements in assessment and collation 
were resolved by discussion. A flow chart of the trial inclusion 
procedure is provided in Fig. 1.
Data extraction, collation, and synthesis
Outcome measures were decided on an a priori basis, so as 
to minimise bias. Primary outcomes included the reduction 
in total symptom severity and the number of treatment 
responders. PTSD symptom severity was determined from the 
total score on the Clinician Administered PTSD Scale (CAPS),9 
a measure increasingly used in RCTs of PTSD. Treatment 
response was determined from the Clinical Global Impressions 
scale-Improvement item (CGI-I),10 or a closely related measure. 
   Secondary outcomes included reduction of the severity 
of PTSD symptom clusters (assessed using the respective 
CAPS subscales), and the response of co-morbid depression 
(measured using scales such as the Beck Depression Inventory 
(BDI)11 and the Hamilton Depression scale (HAM-D)12). 
Quality of life and functional disability measures were 
also included when provided, to address the question of 
medication effectiveness.  The total proportion of participants 
who withdrew from the RCTs because of treatment-emergent 
adverse events were included as a measure of medication 
acceptability.
   Descriptive and outcome summary statistics for each trial 
were captured on customised data-collection forms, and 
subsequently exported to the Review Manager software 
(RevMan version 4.2.8)13 for analysis.  Where information was 
missing, the reviewers contacted investigators by e-mail in an 
attempt to obtain this information. 
Data analysis
Weighted mean differences (WMDs) for continuous measures 
Fig. 1. Flow chart of trial inclusion in meta-analyses.
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and relative risks (RRs) for categorical outcomes were obtained 
from a random effects model and were expressed in terms of 
average effect size for each subgroup, as well as by means of 
95% confidence intervals (CIs). The number needed to treat 
(NNT) was also calculated. The NNT provides an indication of 
the number of patients who require treatment with medication, 
relative to a control, before a single additional patient in the 
medication group responds to treatment. The standardised 
mean difference (SMD) was used instead of the WMD for 
comparisons in which a range of scales were employed. 
   In recognition of the possibility of differential effects for 
different types of medication, all of the comparisons were 
stratified by medication class.  Medications that could not 
be classified as SSRIs, tricyclic antidepressants (TCAs), 
monoamine oxidase inhibitors (MAOIs) or reversible inhibitors 
of monoamine oxidase (RIMAs) were placed in a separate 
category, labelled ‘Other medication’. In addition, it was 
decided, on the basis of the large number of SSRI trials included 
in the review, to stratify the primary outcome measure and 
drop-out comparisons by individual SSRI agents. In the case of 
data from trials employing multiple fixed doses of medication, 
the endpoint mean scores and standard deviations (SDs) were 
pooled across all of the treatment arms as a function of the 
number of participants in each arm.
   Cross-over trials were only included in the calculation 
of summary statistics when it was: (i) possible to extract 
medication and placebo/comparator data from the first 
treatment period; or (ii) when the inclusion of data from both 
treatment periods was justified through a wash-out period of 
a duration sufficient to minimise the risk of carry-over effects 
(a minimum of 2 weeks or longer in the case of trials assessing 
the efficacy of agents with extended half-lives, such as the SSRI, 
fluoxetine14).  
Quality of included studies
Trial quality was assessed by collating data for trial 
characteristics that have been recognised as a potential source 
of systematic bias. These include the method of concealing 
treatment allocation (categorised on a scale from A to C, 
depending on whether the method used was adequate, unclear, 
or inadequate, respectively), as well as whether outcome 
assessment was blinded (A: yes, B: no, C: unclear). 
Heterogeneity
Heterogeneity of treatment response was assessed at the 
0.1 level of significance by means of the chi-square statistic. 
Differences on continuous measures between groups on this 
statistic were assessed by means of Deeks’ stratified test of 
heterogeneity.15 Differences in treatment response on the CGI-I 
were determined by overlap in the CIs for the effect sizes for 
the subgroups tested.  
   Subgroup analyses were undertaken in order to determine 
the degree to which methodological and clinical differences 
between trials might have systematically influenced differences 
observed in the primary treatment outcomes. 
   Criteria used in grouping the trials included: (i) whether 
or not they were conducted at single or multiple centres; (ii) 
whether or not the trials included combat veterans; and (iii) 
whether patients diagnosed with major depressive disorder 
(MDD) were included in the sample. Combat veterans are 
generally regarded as being more resistant to treatment, while 
controlling for the presence of patients with MDD would help 
to determine the extent to which the efficacy of medication in 
combating PTSD is mediated by the antidepressant properties 
of the drugs used. 
Results
Description of studies
The review included 35 short-term RCTs of PTSD (4 597 
participants), 3 of which contained a maintenance component 
(Table I).  Of the 35 trials, 30 were published, and all of these 
publications were in English.  A placebo comparison group was 
employed in all but 4 of the trials.16-19 
Quality of included studies
The majority of the trial reports did not provide sufficient 
information to determine the quality of the studies. Of the 
35 short-term trials, only 6 characterised the assessment of 
outcome as blinded, with 2 comparative RCTs not employing 
any form of blinding.17,18 Even fewer trials described the 
allocation sequence that was used in assigning group 
membership to participants (N = 5).
   Failure to provide sufficient information for the calculation 
of summary statistics prevented the inclusion of data from 
the 4 acute cross-over RCTs in the meta-analysis.20-23 However 
this is unlikely to have had a significant effect on estimates of 
treatment efficacy as these trials were all small. 
   In analysing data from the placebo-controlled trial of 
phenelzine and imipramine,24 only data from the imipramine 
arm were included in the meta-analyses. This reduced the 
disparity in the number of MAOI and TCA trials in the review, 
in keeping with the a priori decision to restrict data inclusion 
from multi-arm trials to the less well-represented medication 
classes, so as to avoid the potential bias of comparing summary 
statistics for multiple medication groups against the same 
placebo control. In the multi-arm trials comparing the SRIs 
citalopram25 and venlafaxine  (unpublished trials, Table I) with 
the SSRI sertraline, the former agents were given preference as 
less well-represented medication agents, for the same reason. 
Primary outcomes
Patients who received medication in the 17 trials providing 
data on the CAPS displayed significantly less severe PTSD 
symptoms at trial endpoint than those who received placebo 
(WMD = −5.76, 95% CI: −8.16 - −3.36, number of participants 
(N) = 2 507).  Evidence was detected for the efficacy of the SSRIs 
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(N = 12, WMD = −5.59, 95% CI: −8.6 - −2.58, N = 1 909), with 
this class of medication making the largest contribution to the 
overall effect size (weight = 82.4%).  
   Comparison of the efficacy of particular SSRIs in reducing 
PTSD symptom severity provided evidence for the efficacy of 
both paroxetine (N = 4, WMD = −10.49, 95% CI: −13.87 - −7.11, 
N = 940) and to a lesser extent, sertraline (N = 6, WMD = −3.78, 
95% CI: −6.9 - −0.65, N = 875). There was no indication that 
brofaromine was more effective than placebo, while the single 
trials of the novel antidepressant nefazodone, the antipsychotic 
risperidone, the selective norepinephrine re-uptake inhibitor 
(SNRI) venlafaxine, and the SSRIs citalopram and fluoxetine 
failed to provide evidence for the efficacy of these medications 
in reducing symptom severity (Fig. 2). 
   Neither the two head-to-head comparisons of nefazodone 
and sertraline, nor the single unpublished comparison of 
venlafaxine and sertraline, detected a difference in the efficacy 
of medication agents in reducing symptom severity. The 
investigators in the only trial to compare mirtazapine and 
sertraline directly17 were unable to detect a difference in efficacy 
when comparing these groups on the total CAPS score. The 
RCT of sertraline in treating concurrent PTSD and co-morbid 
alcoholism26 was not able to detect a difference in the efficacy of 
medication and placebo in reducing symptom severity on the 
CAPS.
   Patients who received medication in the 13 short-term trials 
providing treatment response data on the CGI-I or a related 
measure were significantly more likely to be responders than 
those who received placebo (RR = 1.49, 95% CI: 1.28 - 1.73, 
N =  1 272). Response to medication occurred in 59.1% of 
subjects (N = 644), while response to placebo was seen in 38.5% 
of subjects (N = 628). The short-term efficacy of medication 
treatment was observed for the SSRIs as a group (N = 7, RR = 
1.59, 95% CI:  1.39 - 1.82, N = 999). 
   The pattern of treatment response on the CGI-I for the 
separate SSRI medications was similar to that observed for 
symptom severity, with both paroxetine (N = 3, RR = 1.62, 95% 
CI: 1.38 - 1.9, N = 719) and sertraline (N = 2, RR = 1.71, 95% 
CI:  1.22 - 2.4, N = 215) demonstrating efficacy (Fig. 3). There 
was insufficient evidence to determine whether fluoxetine or 
the MAOI brofaromine was effective in increasing the number 
of responders, relative to placebo. None of the trials of the 
TCA amitriptyline, the novel antidepressant mirtazapine, the 
antipsychotic olanzapine, or the anticonvulsant lamotrigine was 
significantly more effective than placebo in increasing treatment 
response. 
   The NNT analysis revealed that approximately 5 additional 
patients would need to be treated with medication over an 
average period of 11 weeks to achieve 1 additional response, 
relative to placebo (NNT = 4.85). The equivalent number of 
Fig. 2. PTSD symptom severity.
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patients for the individual SSRIs was 4.31 for paroxetine, 4.49 
for sertraline, and 6.07 for fluoxetine. 
   Continued reduction of symptom severity on the CAPS was 
observed in the 10-week extension of the 12-week placebo-
controlled RCT of paroxetine (Marshall RD, Lewis-Fernandez 
R, Blanco C, et al. – unpublished data). An increased rate of 
relapse was observed in those patients randomised to placebo 
after responding to a 12-week trial of fluoxetine.27 Davidson 
and colleagues28 found that over half of the 96 outpatients who 
had initially responded to 6 months of treatment with sertraline 
experienced worsening of symptoms once switched over to 
placebo, with patients in this group being 6.35 times more likely 
to relapse than those participants who remained on medication. 
   Across trials there was little variation in the effectiveness of 
medication in reducing symptom severity (chi-square = 16.3, 
df = 12, p = 0.18) or treatment response. However, separation of 
the effects of the SSRIs by agent revealed that paroxetine was 
more effective in reducing symptom severity than sertraline 
(Qb = 8.86, p < 0.01). Indeed, the reduction of symptom severity 
was more than twice as great for paroxetine as for all the other 
medications combined (WMD = −10.49 versus −4.07). 
   No effect of medication was observed on the symptom 
severity and treatment response outcome measures used in 
any of the placebo-controlled cross-over trials of alprazolam, 
desipramine, inositol, and phenelzine. 
Secondary outcomes
The finding of a significant effect of medication on the re-
experiencing/intrusion (WMD = −2.06, 95% CI:  −3.02 - −1.1, 
N = 1 304), avoidance/numbing (WMD = −4.06, 95%  
CI:  −5.41 - −2.7, N = 1 304), and hyperarousal (WMD = −3.1, 
95% CI:  −4.1 - −2.1, N = 1 304) symptom subscales of the CAPS 
can largely be attributed to the data from the 7 SSRI trials.  The 
remaining trials of nefazodone (N = 1) and risperidone (N = 1) 
Fig. 3. Treatment response.
5
pg 1088-1096.indd   1093 9/22/06   3:36:29 PM
October 2006, Vol. 96, No. 10  SAMJ
ORIGINAL ARTICLES
1094
provided no evidence of efficacy on any 
of the symptom clusters.    
   With regard to co-morbidity, 
medication demonstrated greater 
efficacy in alleviating the symptoms of 
depression than placebo, as assessed by 
a range of depression scales (N = 7, SMD 
= −0.34, 95% CI:  −0.57 - −0.10, N = 459). 
The only head-to-head comparison of 
nefazodone with sertraline for which 
co-morbidity summary statistics were 
available demonstrated that these 
medications were equally effective in 
reducing symptoms of depression. This 
was also the case for the single trial 
comparing mirtazapine and sertraline.
   Quality of life was significantly 
improved by pharmaco- therapy (N = 5, 
WMD = −2.54, 95% CI: −3.68 - −1.41, N = 
752), according to summary statistics on 
the Sheehan Disability Scale (SDS). Once 
again, this was primarily due to the SSRI 
interventions, with only 1 of the 4 trials 
in this class not demonstrably superior 
to placebo in improving functioning.  
Patients receiving medication were 
more likely to withdraw from treatment 
because of side-effects experienced than 
those who received placebo (N = 21, 
RR = 1.44, 95% CI:  1.04 - 2, N = 2 116). 
However this finding could not be 
attributed to the poor tolerability of any 
particular medication class. 
Subgroup analyses
Symptom severity was reduced to a 
greater extent when multiple centres 
participated in a trial (N = 6) than when 
the trial was conducted at a single 
centre (N = 8) (Qb = 2.8, p = 0.09, df = 
13). However this difference was not 
observed with regard to treatment 
response for the comparison of single 
versus multi-centre trials.     
   Symptom severity decreased to an 
equivalent extent (Qb = 0.5, p = 0.48) 
in trials that included depressed 
participants (N = 9) and those that 
did not (N = 2). RCTs that included 
few combat veterans (N = 8, average 
proportion of war veterans = 3%) 
demonstrated a significantly greater 
reduction in symptom severity 
following medication treatment (Qb 
= 4.12, p = 0.04) than trials with a 
large percentage of participants with 
combat-related trauma (N = 4, average 
proportion = 61.1%). The difference 
between these groups was not detected 
with regard to treatment response.
Discussion
This review provides evidence of the 
effectiveness of medication in the short-
term treatment of PTSD, as assessed 
on the primary outcome measures of 
responder status and symptom severity.  
Medication was significantly more 
effective than placebo across the three 
symptom clusters that characterise 
PTSD. In addition, the administration of 
medication resulted in a reduction in co-
morbid symptoms, and improvement in 
quality of life measures.  These findings 
hold despite the clinical heterogeneity of 
PTSD subjects included in the reviewed 
trials (Tables I and II). 
   The current evidence base of RCTs is 
unable to demonstrate superior efficacy 
or acceptability for any particular 
medication class, despite suggestions 
that the SSRIs are more effective and 
tolerable than older antidepressants.29 
Nevertheless, the fact that the SSRI trials 
constitute the bulk of the evidence for 
the efficacy of medication in treating 
PTSD suggests that it is reasonable to 
support the expert consensus30 that 
SSRIs constitute the first-line medication 
choice in PTSD.
   Indeed, it is unlikely that all 
medications are equally effective in 
treating PTSD. While there is evidence 
that paroxetine and sertraline are 
effective in reducing the severity of 
PTSD symptoms, and although the 
two mirtazapine trials provide some 
support for the efficacy of this agent, 
none of the alprazolam, brofaromine, 
desipramine, lamotrigine and 
olanzapine trials demonstrated efficacy 
with regard to treatment response or 
symptom reduction. The question of 
whether benzodiazepines are useful 
immediately after trauma or in PTSD 
remains debated, although recent 
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expert consensus panels have suggested caution in use of these 
agents.7,30 
   The finding that treatment over the longer term results in 
further improvements in efficacy and prevents relapse is 
consistent with the recommended duration of medication 
treatment of 6 - 12 months for acute PTSD,7 and treatment of at 
least 12 months for chronic PTSD.7,30 
   Given the heterogeneous phenomenology of PTSD, it remains 
crucial to conduct further research into the factors, such as age 
and co-morbidity, that may predict response to medication. For 
instance, this review found some evidence that war veterans 
experience less reduction in symptom severity following 
pharmacotherapy than other patient groups. The failure to 
find a similar difference in treatment efficacy for patients with 
and without co-morbid major depression suggests that these 
medications are unlikely to exert their effects indirectly in PTSD 
via a reduction in depressive symptoms. 
   Finally, the inherent problems of meta-analyses should also 
be borne in mind; the quality of a meta-analysis is only as good 
as that of its constituent trials.  The context of clinical practice 
also differs from controlled trials in many respects, such as the 
inclusion in the former of patients with more complex symptom 
presentations and the possible need of polypharmacy in a 
subgroup of patients with PTSD. 
Conclusion
Implications for practice
Medication can be effective in treating PTSD, acting to reduce 
its core symptoms, and should be considered as part of the 
treatment of this disorder. The bulk of evidence for the efficacy 
of medication has, to date, been with the SSRIs and supports 
expert consensus guidelines that these medications constitute 
first-line agents in treating PTSD. The findings of maintenance 
trials support the value of long-term treatment in improving 
efficacy and preventing relapse. 
Implications for research
Additional good-quality controlled trials would help to answer 
questions regarding the differential efficacy and acceptability 
of medication classes, as well as factors predicting response.  
Further research on the value of medication in treating 
PTSD in different trauma and age groups, and in co-morbid 
and treatment-resistant patients, is needed. Clinical trials 
to determine the possible benefits of early, combined (with 
psychotherapy), and long-term intervention in PTSD may also 
be valuable.
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